RTS,S/AS01 Vaccine (Mosquirix™): an Overview

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2019 Sep 24

PMID 31545128

Citations 173

Authors

Matthew B Laurens

Affiliations

Soon will be listed here.

Abstract

Malaria is an illness caused by parasites transmitted to humans by infected mosquitoes. Of the five species that infect humans, exacts the highest toll in terms of human morbidity and mortality, and therefore represents a major public health threat in endemic areas. Recent advances in control efforts have reduced malaria incidence and prevalence, including rapid diagnostic testing, highly effective artemisinin combination therapy, use of insecticide-treated bednets, and indoor residual spraying. But, reductions in numbers of cases have stalled over the last few years, and incidence may have increased. As this concerning trend calls for new tools to combat the disease, the RTS,S vaccine has arrived just in time. The vaccine was created in 1987 and began pilot implementation in endemic countries in 2019. This first-generation malaria vaccine demonstrates modest efficacy against malaria illness and holds promise as a public health tool, especially for children in high-transmission areas where mortality is high.

Citing Articles

Identification and biophysical characterization of Plasmodium peptide binding by common African HLAs.

Frooman M, Choi K, Kahn M, Yang L, Cunningham A, RisCassi J Sci Rep. 2025; 15(1):8614.

PMID: 40074802 PMC: 11903679. DOI: 10.1038/s41598-025-92191-6.

Evasive mechanisms of human VSG and PfEMP1 antigens with link to Vaccine scenario: a review.

Obi O, Obiezue R, Eze D, Adebote D J Parasit Dis. 2025; 49(1):13-28.

PMID: 39975623 PMC: 11833005. DOI: 10.1007/s12639-024-01740-9.

Targeting Bottlenecks in Malaria Transmission: Antibody-Epitope Descriptions Guide the Design of Next-Generation Biomedical Interventions.

Yoo R, Jore M, Julien J Immunol Rev. 2025; 330(1):e70001.

PMID: 39907429 PMC: 11796336. DOI: 10.1111/imr.70001.

PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse immunogenicity studies.

Hickey J, Sharma N, Fairlamb M, Doering J, Adewunmi Y, Prieto K Hum Vaccin Immunother. 2025; 21(1):2460749.

PMID: 39903060 PMC: 11796538. DOI: 10.1080/21645515.2025.2460749.

YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates.

Bouzon-Arnaiz I, Rawat M, Coyle R, Feufack-Donfack L, Ea M, Orban A Sci Rep. 2025; 15(1):2941.

PMID: 39848983 PMC: 11758391. DOI: 10.1038/s41598-025-85346-y.

References

Ballou W, Cahill C . Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals. Am J Trop Med Hyg. 2008; 77(6 Suppl):289-95. View

Neafsey D, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A . Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med. 2015; 373(21):2025-2037. PMC: 4762279. DOI: 10.1056/NEJMoa1505819. View

White M, Verity R, Griffin J, Asante K, Owusu-Agyei S, Greenwood B . Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015; 15(12):1450-8. PMC: 4655306. DOI: 10.1016/S1473-3099(15)00239-X. View

Aide P, Dobano C, Sacarlal J, Aponte J, Mandomando I, Guinovart C . Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine. 2011; 29(35):6059-67. DOI: 10.1016/j.vaccine.2011.03.041. View

Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S . A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One. 2009; 4(10):e7611. PMC: 2763199. DOI: 10.1371/journal.pone.0007611. View

Kester K, Cummings J, Ofori-Anyinam O, Ockenhouse C, Krzych U, Moris P . Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200(3):337-46. DOI: 10.1086/600120. View

Alloueche A, Milligan P, Conway D, Pinder M, Bojang K, Doherty T . Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg. 2003; 68(1):97-101. View

Waitumbi J, Anyona S, Hunja C, Kifude C, Polhemus M, Walsh D . Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One. 2009; 4(11):e7849. PMC: 2773849. DOI: 10.1371/journal.pone.0007849. View

Dame J, Williams J, McCutchan T, Weber J, Wirtz R, Hockmeyer W . Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 1984; 225(4662):593-9. DOI: 10.1126/science.6204383. View

10.

Ishizuka A, Lyke K, DeZure A, Berry A, Richie T, Mendoza F . Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016; 22(6):614-23. PMC: 11294733. DOI: 10.1038/nm.4110. View

11.

Laurens M . The Promise of a Malaria Vaccine-Are We Closer?. Annu Rev Microbiol. 2018; 72:273-292. DOI: 10.1146/annurev-micro-090817-062427. View

12.

Zavala F, Tam J, Hollingdale M, Cochrane A, Quakyi I, Nussenzweig R . Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985; 228(4706):1436-40. DOI: 10.1126/science.2409595. View

13.

Regules J, Cicatelli S, Bennett J, Paolino K, Twomey P, Moon J . Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. J Infect Dis. 2016; 214(5):762-71. DOI: 10.1093/infdis/jiw237. View

14.

Kurtovic L, Agius P, Feng G, Drew D, Ubillos I, Sacarlal J . Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure. BMC Med. 2019; 17(1):45. PMC: 6388494. DOI: 10.1186/s12916-019-1277-x. View

15.

Dobano C, Sanz H, Sorgho H, Dosoo D, Mpina M, Ubillos I . Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nat Commun. 2019; 10(1):2174. PMC: 6520358. DOI: 10.1038/s41467-019-10195-z. View

16.

Seder R, Chang L, Enama M, Zephir K, Sarwar U, Gordon I . Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341(6152):1359-65. DOI: 10.1126/science.1241800. View

17.

Dobano C, Santano R, Vidal M, Jimenez A, Jairoce C, Ubillos I . Differential Patterns of IgG Subclass Responses to Antigens in Relation to Malaria Protection and RTS,S Vaccination. Front Immunol. 2019; 10:439. PMC: 6428712. DOI: 10.3389/fimmu.2019.00439. View

18.

Lyke K, Ishizuka A, Berry A, Chakravarty S, DeZure A, Enama M . Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017; 114(10):2711-2716. PMC: 5347610. DOI: 10.1073/pnas.1615324114. View

19.

Thwing J, Eisele T, Steketee R . Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Public Health. 2011; 11 Suppl 3:S14. PMC: 3231887. DOI: 10.1186/1471-2458-11-S3-S14. View

20.

Moncunill G, Mpina M, Nhabomba A, Aguilar R, Ayestaran A, Sanz H . Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees. Clin Infect Dis. 2017; 65(5):746-755. PMC: 5850568. DOI: 10.1093/cid/cix429. View